Bharat Book Bureau

Bharatbook added a new report on “China Diabetes Market Report & Outlook For 2010-2015” gives a deep insight into the Chinese diabetes market.

China Diabetes Market Report & Outlook For 2010-2015

As the second largest economy of the world, China enjoys pink of health but its affluence is giving rise to another sickness- a rapid increase in a life-style disease called diabetes. With the Chinese Population getting richer, fatter and less mobile, there has been a surge in the prevalence of diabetes. Further fuelled by rising disposable incomes, the diabetes market- Non-Insulin Anti-diabetics and Insulin, is expanding by more than 25% percent a year, and thus creating lucrative opportunities for global pharmaceutical companies at a time when rates in the more developed markets have declined. ( )

China’s diabetes market grew at CAGR of 26% in the last five years with sales touching US$ 642 Million in 2009. In a country with around 10% of the total population being above 65 years of age, nearly 100 Million people obese and overweight, and with urbanization rates in an increasing mode, we expect the market to more than quadruple vis-à-vis its present level by 2015.

The research study serves as an analytical as well as statistical tool to understand the epidemiology, trends, market structure and segmentation, competitive landscape, drivers, restraints and the outlook of the diabetes market in China. The report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are looking to foray into the Chinese diabetes market in some form or the other.

Report Highlights

• Driven by strong performance of both Insulin and Non-Insulin Anti-diabetics, The Chinese diabetes market is expected to exceed US$ 2.8 Billion by 2015.
• In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 357 Million. Four of the top five players were foreign multinationals, with Bayer being the leader with a 28% market share.
• Alpha Glycosidase Inhibitors represented the biggest non Insulin Anti-diabetes class with a share of 35% in 2009.
• Although DPP-IV Inhibitors have been available in China only since march 2010. We expect this class to show a strong uptake in the next five years and reach revenues worth US$ 172 Million.
• China’s Insulin market witnessed a CAGR growth of 31% between 2005-2009 and was worth US$ 285 Million in 2009.
• The Chinese Insulin market is strongly oligopolistic with top three players (all of them being multinationals) accounting for 92% of the total sales in 2009. In fact, one player (Novo Nordisk) accounted 71% of the total sales.

For more information kindly visit :
Related Reports

Diabetes Therapies & Diagnostics: Global Markets

Global Diabetes Care Devices Investment Opportunities Analysis and Forecasts to 2012


Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Follow us on twitter:
Please visit our blog at

Author :